Below is a list of our ongoing clinical trials, sponsoring agencies, and associated clinical conditions.
Diabetic Macular Edema
Diabetic Retinopathy Clinical Research Network
Treatment for Central-Involved Diabetic Macular Edema in Eyes with Very Good Visual Acuity (Protocol V).
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multicenter Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects with Diabetic Macular Edema.
Astellas Pharma Europe
A Phase 2, Double-Masked, Randomized, Active Controlled Study to Evaluate the Efficacy and Safety of ASP8232 in Reducing Central Retinal Thickness in Subjects with Diabetic Macular Edema (VIDI).
Ocriplasmin (Jetrea) Research to Better Inform Treatment (ORBIT).
Nova Southeastern University
Phase 1 Study of Optical Coherence Tomography Images to Identify the Prevalence of Vitreomacular Adhesion and Associated Maculopathies (VAST).
Age-Related Macular Degeneration
A Two-Year, Randomized, Double-Masked, Multicenter, Three-Arm Study Comparing the Efficacy and Safety of RTH258 versus Aflibercept in Subjects with Neovascular Age-Related Macular Degeneration (HAWK).
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients with Neovascular Age-Related Macular Degeneration (ONYX).
Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients with Neovascular Age-Related Macular Degeneration (SEQUOIA).
A Phase 3 Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution, 0.2% Twice Daily in Subjects with Neovascular Age-Related Macular Degeneration (MAKO).
Non-Proliferative Diabetic Retinopathy
A Phase 2, Randomized, Double Masked, Sham Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Ocriplasmin In Inducting Total Posterior Vitreous Detachment in Subjects with Non-Proliferative Diabetic Retinopathy (CIRCLE).